European Commission launched a call for Joint Technology Initiative

Tuesday 19 August 2014

Print this page

Recently, the European Commission launched a call for the Joint Technology Initiative innovative medicines 2 (Innovative Medicines Initiative 2 - IMI 2). This is the first call for this new JTI for the period 2014-2020 (see ETPJTI). The budget for the call is € 49.26 million. Proposals may be submitted until November 12, 2014 (17:00).


The call with identifier H2020-JTI-IMI2-2014-01 is open regarding 2 topics:


Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)

The overall aim of a project should be to significantly progress the understanding of the T1DM disease and its patients by bringing together leading clinicians and researchers from the areas of immunology, beta cell biology, and biomarker research from academia and industry. It is expected that this initiative will significantly progress the molecular understanding of the pathophysiology of T1DM and of the impact provided by standard of medical care upon T1DM patients. The project should help to gain an improved molecular understanding of the T1DM patients, deliver insights into the disease heterogeneity and provide tools for identification of high-risk patients. Ultimately the outcome will be the definition and refinement of T1DM disease taxonomy which could create a foundation for personalized therapy of T1DM patients. More information: please download the full topic text of IMI 2 Call 1.


Discovery and validation of novel endpoints in dry age-related macular degeneration and diabetic retinopathy

The aim is to evaluate novel endpoint candidates for dry AMD and DR. The evaluation should cover the technical, medical and health economic appropriateness of a method and bridge preclinical and clinical studies. The project should provide generation of adequate data resulting from robust retrospective and/or prospective studies in patients that could serve as basis for initial discussion with regulatory agencies and/or HTA-bodies for acceptance of the resulting outcomes as endpoints for future clinical programs. More information: please download the full topic text of IMI2 Call 1.


For more information, see


Feel free to contact the Campus’ Tailored Approach to Grants (#TAG) helpdesk regarding any questions or support requests in terms of grant project management. Please also keep in mind that the Vouchers of the Campus could help you to write a winning proposal.




Save the date:  12-11-2014!